171 related articles for article (PubMed ID: 11412781)
1. [Diabetes mellitus, inflammation and coronary atherosclerosis: current and future perspectives].
Sánchez-Recalde A ; Carlos Kaski J
Rev Esp Cardiol; 2001 Jun; 54(6):751-63. PubMed ID: 11412781
[TBL] [Abstract][Full Text] [Related]
2. Peroxisome proliferator activated receptor gamma and its activation in the treatment of insulin resistance and atherosclerosis: issues and opportunities.
Beckman J; Raji A; Plutzky J
Curr Opin Cardiol; 2003 Nov; 18(6):479-85. PubMed ID: 14597889
[TBL] [Abstract][Full Text] [Related]
3. The potential role of peroxisome proliferator-activated receptors on inflammation in type 2 diabetes mellitus and atherosclerosis.
Plutzky J
Am J Cardiol; 2003 Aug; 92(4A):34J-41J. PubMed ID: 12957325
[TBL] [Abstract][Full Text] [Related]
4. The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients.
Sidhu JS; Cowan D; Kaski JC
J Am Coll Cardiol; 2003 Nov; 42(10):1757-63. PubMed ID: 14642684
[TBL] [Abstract][Full Text] [Related]
5. Metabolic and additional vascular effects of thiazolidinediones.
Martens FM; Visseren FL; Lemay J; de Koning EJ; Rabelink TJ
Drugs; 2002; 62(10):1463-80. PubMed ID: 12093315
[TBL] [Abstract][Full Text] [Related]
6. Peroxisome proliferator-activated receptor-alpha and atherosclerosis: from basic mechanisms to clinical implications.
Israelian-Konaraki Z; Reaven PD
Cardiology; 2005; 103(1):1-9. PubMed ID: 15528894
[TBL] [Abstract][Full Text] [Related]
7. Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus.
Ríos-Vázquez R; Marzoa-Rivas R; Gil-Ortega I; Kaski JC
Am J Cardiovasc Drugs; 2006; 6(4):231-42. PubMed ID: 16913824
[TBL] [Abstract][Full Text] [Related]
8. Role of PPARs in the regulation of obesity-related insulin sensitivity and inflammation.
Moller DE; Berger JP
Int J Obes Relat Metab Disord; 2003 Dec; 27 Suppl 3():S17-21. PubMed ID: 14704738
[TBL] [Abstract][Full Text] [Related]
9. [Peroxisome proliferator-activated receptors and atherosclerosis].
Jin N; Wang X
Sheng Li Ke Xue Jin Zhan; 2004 Jan; 35(1):13-8. PubMed ID: 15127591
[TBL] [Abstract][Full Text] [Related]
10. Peroxisome proliferator-activated receptors: how their effects on macrophages can lead to the development of a new drug therapy against atherosclerosis.
Li AC; Palinski W
Annu Rev Pharmacol Toxicol; 2006; 46():1-39. PubMed ID: 16402897
[TBL] [Abstract][Full Text] [Related]
11. A rational approach to pathogenesis and treatment of type 2 diabetes mellitus, insulin resistance, inflammation, and atherosclerosis.
Dandona P; Aljada A
Am J Cardiol; 2002 Sep; 90(5A):27G-33G. PubMed ID: 12231076
[TBL] [Abstract][Full Text] [Related]
12. Peroxisome proliferator-activated receptor gamma agonists: their role as vasoprotective agents in diabetes.
Blaschke F; Caglayan E; Hsueh WA
Endocrinol Metab Clin North Am; 2006 Sep; 35(3):561-74, ix. PubMed ID: 16959586
[TBL] [Abstract][Full Text] [Related]
13. What are the effects of peroxisome proliferator-activated receptor agonists on adiponectin, tumor necrosis factor-alpha, and other cytokines in insulin resistance?
Boyle PJ
Clin Cardiol; 2004 Jul; 27(7 Suppl 4):IV11-6. PubMed ID: 15470906
[TBL] [Abstract][Full Text] [Related]
14. [Peroxisome proliferator activated nuclear receptors: possible role in the development of atherosclerosis].
Evdokimova MA; Zateĭshchikov DA; Sidorenko BA
Kardiologiia; 2003; 43(11):41-8. PubMed ID: 14671562
[TBL] [Abstract][Full Text] [Related]
15. [Peroxisome proliferator activated receptors PPARs: their role in carbohydrate and lipid metabolism].
Andrééva-Gatéva P
Ann Biol Clin (Paris); 2003; 61(3):295-303. PubMed ID: 12805006
[TBL] [Abstract][Full Text] [Related]
16. Inflammation and the etiology of type 2 diabetes.
Sjöholm A; Nyström T
Diabetes Metab Res Rev; 2006; 22(1):4-10. PubMed ID: 15991254
[TBL] [Abstract][Full Text] [Related]
17. Implications of resistin in type 2 diabetes mellitus and coronary artery disease: Impairing insulin function and inducing pro-inflammatory cytokines.
Emamalipour M; Seidi K; Jahanban-Esfahlan A; Jahanban-Esfahlan R
J Cell Physiol; 2019 Dec; 234(12):21758-21769. PubMed ID: 31187484
[TBL] [Abstract][Full Text] [Related]
18. Peroxisome proliferator-activated receptor gamma in diabetes and metabolism.
Rangwala SM; Lazar MA
Trends Pharmacol Sci; 2004 Jun; 25(6):331-6. PubMed ID: 15165749
[TBL] [Abstract][Full Text] [Related]
19. Physiological and therapeutic roles of peroxisome proliferator-activated receptors.
Berger J; Wagner JA
Diabetes Technol Ther; 2002; 4(2):163-74. PubMed ID: 12079620
[TBL] [Abstract][Full Text] [Related]
20. Peroxisome proliferator-activated receptors as molecular targets for drug therapy.
Sridhar GR
J Assoc Physicians India; 2003 Jan; 51():49-52. PubMed ID: 12693455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
